These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32369612)

  • 1. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
    Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
    Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
    [No Abstract]   [Full Text] [Related]  

  • 2. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.
    Zhang X; Song K; Tong F; Fei M; Guo H; Lu Z; Wang J; Zheng C
    Blood Adv; 2020 Apr; 4(7):1307-1310. PubMed ID: 32243501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early tocilizumab treatment could improve survival among COVID-19 patients.
    Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
    Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
    [No Abstract]   [Full Text] [Related]  

  • 4. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
    Perricone C; Conigliaro P; Ciccacci C; Marcucci E; Cafaro G; Bartoloni E; Perricone R; Novelli G; Borgiani P; Gerli R
    Clin Exp Rheumatol; 2020; 38(3):580. PubMed ID: 32452345
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 in hem/onc news.
    Schuyler D
    Clin Adv Hematol Oncol; 2020 May; 18(5):248. PubMed ID: 32628651
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
    Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
    Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
    Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
    Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of tocilizumab effect on mortality in COVID19 patients.
    Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
    Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
    Mojtabavi H; Saghazadeh A; Rezaei N
    Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
    Vikse J; Henry BM
    Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
    [No Abstract]   [Full Text] [Related]  

  • 12. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
    Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A
    Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824
    [No Abstract]   [Full Text] [Related]  

  • 13. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
    Ledford H
    Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
    [No Abstract]   [Full Text] [Related]  

  • 14. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
    Wang L; Peng X; Wang ZH; Cai J; Zhou FC
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine Storm Drugs Move from CAR T to COVID-19.
    Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
    Gade AR; Alavala H; Allam SR
    Kidney Int; 2020 Oct; 98(4):1054. PubMed ID: 32650019
    [No Abstract]   [Full Text] [Related]  

  • 17. Effective treatment of severe COVID-19 patients with tocilizumab.
    Xu X; Han M; Li T; Sun W; Wang D; Fu B; Zhou Y; Zheng X; Yang Y; Li X; Zhang X; Pan A; Wei H
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10970-10975. PubMed ID: 32350134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine release syndrome in severe COVID-19.
    Moore JB; June CH
    Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    Zhao M
    Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.
    Solis-García Del Pozo J; Galindo MF; Nava E; Jordán J
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7475-7484. PubMed ID: 32706087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.